FGP
APGE icon

Freestone Grove Partners’s Apogee Therapeutics APGE Stock Holding History

Freestone Grove Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133 Buy
+1
New +$90 ﹤0.01% 919

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Freestone Grove Partners's APGE Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 1 share worth $133. The stake represents ﹤0.01% of the portfolio and ranks #919 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Freestone Grove Partners held 1 share of Apogee Therapeutics worth $133 as of Q2 2026.
  • Apogee Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #919 holding.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.